Evidence map›Paper›PMID 29179867›Full record

ArticlePapillomavirus research (Amsterdam, Netherlands)2017

HPV vaccination of immunocompromised hosts.

S M Garland, J M L Brotherton, A B Moscicki, A M Kaufmann, M Stanley, N Bhatla, R Sankaranarayanan, S de Sanjosé, J M Palefsky, IPVS

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Papillomavirus research (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Promoting HPV Vaccination in People with HIV: Factors to Consider.International journal of environmental research and public health · 2023
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 7 countries.

S M GarlandDepartment of Microbiology and Infectious Diseases, Royal Women's Hospital, 30 Flemington Road, Parkville 3052, Australia; Murdoch Childrens Research Institute, 50 Flemington Road, Parkville 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Parkville 3052, Australia. Electronic address: Suzanne.Garland@thewomens.org.au.
J M L BrothertonVCS Registries, Victorian Cytology Service, Level 6, 176 Wellington Parade, East Melbourne 3002, Australia; School of Population and Global Health, University of Melbourne, Parkville 3052, Australia. Electronic address: jbrother@vcs.org.au.
A B MoscickiDepartment of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave. MDCC 22-432, MC:175217, Los Angeles, CA 90095, United States. Electronic address: AMoscicki@mednet.ucla.edu.
A M KaufmannGynäkologische Tumorimmunologie, R. 4503 Gynäkologie, Charite-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. Electronic address: Andreas.Kaufmann@charite.de.
M StanleyDepartment of Pathology, Tennis Court Road, Cambridge CB2 1QP, United Kingdom. Electronic address: mas1001@cam.ac.uk.
N BhatlaDepartment of Obstetrics & Gynaecology, All India Institute of Medical Sciences, New Delhi 110029, India. Electronic address: neerja.bhatla07@gmail.com.
R SankaranarayananScreening Group, Section of Early Detection and Prevention, International Agency for Research on Cancer, World Health Organization, 150 cours Albert Thomas, 69372 Lyon CEDEX 08, France. Electronic address: sankar@iarc.fr.
S de SanjoséCancer Epidemiology Research Programme, IDIBELL, CIBERESP, Institut Català d'Oncologia, Av. Gran Via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Spain. Electronic address: desanjose.silvia@gmail.com.
J M PalefskyUniversity of California, San Francisco, 513 Parnassus Ave Box 0654, San Francisco, CA 94143, United States. Electronic address: joel.palefsky@ucsf.edu.
IPVS
University of Melbourne · AUAll India Institute of Medical Sciences · INCentre International de Recherche sur le Cancer · FRCharité - Universitätsmedizin Berlin · DEInstitut d'Investigació Biomédica de Bellvitge · ESLawn Tennis Association · GBUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

It is well-established that immunocompromised people are at increased risk of HPV-related disease compared with those who are immunocompetent. Prophylactic HPV sub-unit vaccines are safe and immunogenic in immunocompromised people and it is strongly recommended that vaccination occur according to national guidelines. When delivered to immunocompromised populations, HPV vaccines should be given as a 3-dose regimen.

Indexed as

Immunocompromised HostAdolescentChildFemaleGuidelines as TopicHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18HumansImmunogenicity, VaccinePapillomavirus InfectionsPapillomavirus VaccinesVaccinationHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Papillomavirus VaccinesHPV GuidelinesHPV related cancersHuman papillomavirus (HPV)Immunocompromised hostsVaccination

Identifiers

PMID29179867
PMCPMC5883202
OpenAlexW2620730943

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.